KB-1776

RG6333

61520

Background of RG6333

RG6333 (CD19-CD28) is a heterodimeric 1+1 IgG1-based CD19-targeted bispecific antibody containing a low affinity, monovalent anti-CD28 binding moiety and a silent Fc-domain aiming to provide a strong but safe "signal II'' to activated T cells. Unlike CD28 superagonists that induce T cell activation and strong toxicity in human in the absence of a "signal I", RG6333 strictly depends on the presence of a "signal I" for activity due to its unique properties. It is designed to neither exhibit single-agent activity nor induce cytokine-release syndrome (CRS) but to further boost intratumoral T cell effector function and tumor cell killing once "signal I" (i.e. glofitamab) is provided.

Specifications

Catalog Number	KB-1776
Antibody Name	RG6333
Isotype	Human IgG1,kappa
FC Muations	HC1: L234A/L235A/P329G/Y349C/T366S/L368A/Y407V/G446Del/K447Del HC2: K147E/K213E/L234A/L235A/P329G/S354C/T366W/G446Del/K447Del
Target	CD19xCD28
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Sam J, Hofer T, Kuettel C, Claus C, Thom J, Herter S, Georges G, Korfi K, Lechmann M, Eigenmann MJ, Marbach D, Jamois C, Lechner K, Krishnan SM, Gaillard B, Marinho J, Kronenberg S, Kunz L, Wilson S, Briner S, Gebhardt S, Varol A, Appelt B, Nicolini V, Speziale D, Bez M, Bommer E, Eckmann J, Hage C, Limani F, Jenni S, Schoenle A, Le Clech M, Vallier JP, Colombetti S, Bacac M, Gasser S, Klein C, Umaña P. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy. Blood. 2024 May 23;143(21):2152-2165.